Clinical Trial Update: Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 1]

View source ↗

Summary

A Phase 1 study assessed the safety and tolerability of several inhaled doses of NVA237 in patients with chronic obstructive pulmonary disease; the trial comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Status: COMPLETED